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Epigenetics  alterations,  including  aberrant  DNA  methylation,  have  been  associated  with  gastric  carcino-
genesis.  Single  nucleotide  polymorphisms  (SNPs)  in DNA methyltransferases  (DNMTs)  may  inﬂuence
protein  expression  and  therefore  affect DNA  regulation  and  susceptibility  for Gastric  Cancer  (GC).
We  have  performed  a  systematic  review  and  meta-analysis  involving  11  studies  and  a total  of 24 SNPs
in  DNMTs  were  analyzed.  According  to literature,  only  4 SNPs,  DNMT1  rs16999593,  DNMT2  rs11254413
and  DNMT3A  rs7560488  and  DNMT3A  rs36012910,  were  associated  with  GC.  DNMT1  rs16999593  and
DNMT3A  rs7560488C  allele  and  DNMT3A  rs36012910  G  allele  showed  an  increased  risk  for  GC.  On  the
other  hand,  DNMT2  rs11254413  G allele presented  a protective  effect  for GC.  Additionally,  the meta-
analysis  evaluated  the  SNPs  analyzed  in  more  than  one  study (n =  6).  Results  revealed  that only  DNMT1
rs16999593  had  a  statistically  signiﬁcant  association  with  GC development  (OR  = 1.31; 95%  CI  = 1.08–1.60;
p  =  0.006  for  TC  +  CC  genotypes).
Our  study  suggests  that DNMT2  rs11254413,  DNMT3A  rs7560488,  DNMT3A  rs36012910  and,  specially,
DNMT1  rs16999593  may  have  an  association  with  GC  development.  Nevertheless,  further  studies  are
need using  different  populations  to clarify  this  association  with  GC risk.
© 2016  PBJ-Associac¸a˜o  Porto  Biomedical/Porto  Biomedical  Society.  Published  by  Elsevier  Espan˜a,
en  acS.L.U.  This  is an op
ntroduction
Epigenetics, and more extensively DNA methylation, has been
tudied in the past decades and associated with several diseases,
ncluding cancer. Literature shows that altered epigenetic control
f gene expression has an important role in carcinogenesis.1 DNA
ethylation is an important epigenetic mark in tumorigenesis, in
hich a methyl group is added to the 5′ position of the cytosine
esidue in a CpG dinucleotide (CpG islands, CGI), in the 5′-ﬂanking
romoter’s genes.2 Aberrant methylation of promoter’s genes is
n important hallmark of cancer cells and, in Gastric Cancer (GC),
 large number of genes involved in carcinogenesis and clinical
utcome accumulate aberrant methylation. Promoter methylation
s an important mechanism of inactivation of tumour suppressor
enes, in cancer cells.2
∗ Corresponding author.
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H. Sousa).
http://dx.doi.org/10.1016/j.pbj.2016.10.005
444-8664/© 2016 PBJ-Associac¸a˜o Porto Biomedical/Porto Biomedical Society. Publishe
icense (http://creativecommons.org/licenses/by-nc-nd/4.0/).cess  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
The process of promoter methylation is catalyzed by DNA
methyltransferases (DNMTs) which organize, regulate and main-
tain properly mammalian genomes.3 Literature describes three
types of DNMTs: DNMT1, over-expressed in human cancers
including GC, that catalyze post-replication DNA methylation
and maintain the methylation patterns during cell divisions4–6;
DNMT2, which is the most conserved and has a role in both DNA
and RNA methylation7; and DNMT3, which is divided into two
types (DNMT3a and DNMT3b) that are responsible for de novo
methylation during gametogenesis and embryogenesis, and that
also seem to be over-expressed in human cancers, including GC.3,6
Recently, literature has suggested that single nucleotide polymor-
phisms (SNPs) in DNMTs could promote functional consequences
affecting methylation and therefore individual’s susceptibility to
cancer development.6,8
Several studies have reported a potential association between
SNPs in DNMTs and the GC susceptibility.3,9–11 Nevertheless, the
observed associations of these studies are inconsistent and some
studies are not large enough to take conclusions on the effect of
DNMTs SNPs on GC. As a result, we have performed a systematic
d by Elsevier Espan˜a, S.L.U. This is an open access article under the CC BY-NC-ND
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eview and meta-analysis of all eligible studies to understand the
ossible association of SNPs in DNMTs genes and GC susceptibility.
aterials and methods
earch strategy
The present systematic review and meta-analysis followed
RISMA guidelines for Systematic Review and Meta-analyses. Liter-
ture was searched on PubMed data base until March 2016 applying
he following query: “dna modiﬁcation methylases”[MeSH Terms]
R (“dna”[All Fields] AND “modiﬁcation”[All Fields] AND “methy-
ases”[All Fields]) OR “dna modiﬁcation methylases”[All Fields] OR
“dna”[All Fields] AND “methyltransferase”[All Fields]) OR “dna
ethyltransferase”[All Fields] OR DNMT[All Fields]) AND (“poly-
orphism, genetic”[MeSH Terms] OR (“polymorphism”[All Fields]
ND “genetic”[All Fields]) OR “genetic polymorphism”[All Fields]
R “polymorphism”[All Fields]) AND (“stomach neoplasms”[MeSH
erms] OR (“stomach”[All Fields] AND “neoplasms”[All Fields]) OR
stomach neoplasms”[All Fields] OR (“gastric”[All Fields] AND “can-
er”[All Fields]) OR “gastric cancer”[All Fields].
nclusion and exclusion criteria
The literature search was limited to original studies per-
ormed in humans and no publication year restriction was  applied.
nly case–control studies with histologically-conﬁrmed adeno-
arcinoma cases were included in this analysis. All DNMTs
olymorphisms were selected for the analysis. Regarding the lan-
uage of the papers, only studies written in English, Portuguese
r Spanish were selected. Reviews, Meta-analysis, Systematic
eviews and studies not related to gastric cancer were excluded
rom this analysis.
ata extraction
Two authors performed the data extraction and all disagree-
ents were resolved with the opinion of a third author. For each
tudy, the following items were collected: country, type of study,
thnicity, matching criteria, age (years), polymorphisms, genotype
ethod, and the number of cases and controls. Data concerning
enotype distribution and the relative risk were also extracted for
ll polymorphisms included in the studies.
tatistical analysis
The evidence of Hardy Weinberg Equilibrium (HWE) in con-
rols was recalculated in the present meta-analysis through the
pplication of the online software (http://www.had2know.com/
cademics/hardy-weinberg-equilibrium-calculator-2-alleles.html)
 p-value less than 0.05 of HWE  was considered signiﬁcant.
Meta-analysis for DNMTs SNPs was conducted by using the
oftware Review Manager, version 5.3.5 (Copenhagen: The Nordic
ochrane Centre, The Cochrane Collaboration, 2014). The calcu-
ated OR (95% CI) was performed with Mantel–Haenszel statistical
ethod and Random effects analysis model. A p-value less than
.05 was considered signiﬁcant.
esults
iterature searchA total of 35 papers were evaluated from which only 11 matched
nclusion criteria. Seventeen articles were excluded due to the
xclusion criteria by screening the titles and abstracts. After a. J. 2016;1(5):164–172 165
comprehensive evaluation of the remaining 18 articles, a total
of 7 studies were excluded: 4 articles did not evaluate polymor-
phisms of DNMTs, only O6-methylguanine-DNA methyltransferase
(MGMT)12–15; 2 articles only reported mutations on DNMTs5,16; 1
study was about allelic loss in gastric cancer.17 Finally, 11 studies
involving a total of 3049 cases and 5185 controls were included in
this analysis – Fig. 1.
Study characteristics
Table 1 describes the principal baseline characteristics of
included studies. The majority of the studies were performed in
China,3,8–11,18–21 one study in Iran22 and one in Japan.23 Almost all
studies have selected the controls and cases using age and gender
as matching criteria, but some studies also used Helicobacter pylori
infection status and Ethnicity. The number of cases and controls
varies between the studies. A total of 24 polymorphisms were eval-
uated, 10 of DNMT1, 1 of DNMT2, 6 of DNMT3A and 7 of DNMT3B.
The majority of studies were performed using Polymerase Chain
Reaction–Restriction Fragment Length Polymorphism (PCR-RFLP)
methodology, but other methods of genotyping were used like Taq-
Man  assay, High Resolution Melting (HRM) and Matrix Assisted
Laser Desorption/Ionization – Time of Flight (MALDI-TOF). Supple-
mentary Table 1 shows the characteristics of all polymorphisms
included in the studies. The re-calculated HWE  for controls is also
shown in supplementary Table 2.
Genotyping results
The genotyping results of all studies are described in Table 2.
A total of 10 SNPs in DNMT1 were studied by 3 different stud-
ies and only rs16999593, rs8101866 and rs2228611 have data
from more than one population3,11,22 – Table 2.1. The risk analysis
revealed that only one study reported a signiﬁcant risk association
(rs16999593) with GC development (OR = 1.45; 95% CI = 1.00–2.11;
p = 0.05, for C allele).
Only one study evaluated SNPs in DNMT2 and GC, revealing
that rs112254413 A allele was associated with a protection for
the development of GC (OR = 0.15; 95% CI = 0.08–0.27; p < 0.01)3 –
Table 2.2.
Thirteen SNPs of DNMT3 (6 from DNMT3A and 7 from
DNMT3B) were evaluated by 9 different studies3,8–10,19–21,23,24 –
Tables 2.3 and 2.4. The risk analysis have shown that DNMT3A
rs7560488 (OR = 1.65; 95%CI = 1.19–2.29; p = 0.002, for C allele) and
rs36012910 (OR = 2.36; 95%CI = 1.35–4.14; p = 0.002, for allele G)
seem to be associated with an increased risk for GC.8,19 On the
other hand, DNMT3A rs1550117 and rs13420867 show contra-
dictory ﬁndings between the reported studies. In DNMT3B, only
rs1569686 showed a statistically signiﬁcant association (p < 0.01)
with GC, nevertheless the results are contradictory among the dif-
ferent studies.
Meta-analysis results
The meta-analysis was  performed with data from all SNPs eval-
uated in more than one study – Figs. 2–4. A total of 6 SNPs
were analyzed: DNMT1 rs16999593, rs8101866 and rs2228611;
DNMT3A rs1550117 and rs13420827; and DNMT3B rs1569686. For
the analysis, we have used the dominant genetic model, considering
the risk genotype as the presence of any copy of the less fre-
quent allele. We  have also tested all data considering the Recessive
Model for each SNP, and no signiﬁcant change was observed in the
reported data (data not shown). The majority of studies showed no
signiﬁcant heterogeneity in the data reported (p > 0.05).
DNMT1: The analysis revealed no genetic heterogeneity
(p > 0.05) amongst the three SNPs tested. We  found that only
166
 
M
.
 N
eves
 et
 al.
 /
 Porto
 Biom
ed.
 J.
 2016;1(5):164–172
Table 1
Characteristics of all studies included in the analysis.
Reference Country (Ethnicity) Matching Criteria Cases Controls Gene SNPS (rs) Genotype method
n Age n Age
Wang et al., 2015 China (Asian) Age, Gender and H. pylori 447 NA 961 NA DNMT3b rs6119954,
rs1569686,
rs4911107,
rs4911259,
rs8118663
TaqMan assay
Wu  et al., 2014 China (Asian) Age and Gender 405 NA 408 NA DNMT3a rs7560488 High resolution melting
Cao  et al., 2013 China (Asian) Age, Gender and H. pylori 447 61.6 961 50.6 DNMT3a rs1550117,
rs13420827
TaqMan assay
Wu  et al., 2012 China (Asian) Age and Gender 340 62.2* 251 62.7* DNMT3a rs36012910 PCR-RFLP
Jiang  et al., 2012 China (Asian) Age, Gender and H. pylori 447 61.6 961 50.6 DNMT1 rs10420321,
rs16999593,
rs8101866,
rs8111085,
rs2288349
TaqMan assay
Yang  et al., 2012 China (Asian) Age and Gender 242 54.9 ± 12.5 294 58.4 ± 16.4 DNMT3a
DNMT3b
DNMT1
DNMT2
rs16999593,
rs8101866,
rs2228611,
rs2114724,
rs11254413,
rs1550117,
rs13420827,
rs11887120,
rs13428812,
rs2424908
MALDI-TOF
Fan  et al., 2010 China (Asian) Age and Gender 208 65 346 71 DNMT3a rs1550117 PCR-RFLP
Hu  et al., 2010 China (Asian) Age and Gender 259 64.0 262 65.1 DNMT3b rs1569686,
rs2424913
PCR-RFLP
Khatami  et al., 2009 Iran (Turk and Fars) Age, Gender and ethnicity 200 50 ± 13 200 58 ± 13 DNMT1 rs721186,
rs13784,
rs2228611,
rs11488
PCR-RFLP
Aung  et al., 2005 Japan (Asian) NA 152 64.1* 247 43.9* DNMT3b rs2424913 PCR-RFLP
Wang  et al., 2005 China (Asian) Age and Gender 212 60.4 294 59.1 DNMT3b rs2424913 PCR-RFLP
NA, not available; * Median (range); H. pylori – Helicobacter pylori; DNMT1 – DNA (cytosine-5)-methyltransferase 1; DNMT2 – TRNA (cytosine38-C5)-methyltransferase; DNMT3a – DNA (cytosine-5)-methyltransferase 3 alpha;
DNMT3b  – DNA (cytosine-5-)-methyltransferase 3 beta; MALDI-TOF – Matrix-Assisted Laser Desorption/Ionization-Time of Flight; PCR-RFLP – Polymerase Chain Reaction-Restriction Fragment Length Polymorphism.
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Table 2.1
Genotyping results for DNMT1 of all studies included.
Gene SNP Genotype distribution n (%) Analysis model OR (CI) p value Reference
Cases Controls
DNMT1
rs10420321 AA AG GG AA AG GG
141  (31.5) 203 (51.5) 76 (17) 328 (34.1) 454 (47.2) 179 (18.6) CD 1.17 (0.88–1.55) (GG) 0.29 Jiang 2012
rs16999593 TT TC CC TT TC CC
283  (63.3) 144 (32.2) 20 (4.5) 659 (68.6) 273 (28.4) 29 (3) CD 1.25(0.95–1.66) (CT) 0.18 Jiang 2012
141  (58.3) 89 (36.8) 12 (5) 196 (66.7) 83 (28.2) 15 (5.1) CD 1.47 (1.01–2.14) (TC) 0.11 Yang 2012
Dominant 1.45 (1.00–2.11) (TC + CC) 0.05
rs8101866 CC CT TT CC CT TT
238  (53.5) 177 (39.8) 30 (6.7) 489 (50.9) 402 (41.8) 70 (7.3) CD 0.81 (0.18–1.35) (CT) 0.11 Jiang 2012
13  (5.4) 98 (40.1) 130 (53.9) 26 (8.8) 102 (34.7) 166 (56.5) CD 1.20 (0.83–1.74) (TC) 0.17 Yang 2012
Dominant 1.27 (0.89–1.82) (TC + CC) 0.19
rs8111085 TT TC CC TT TC CC
143  (32) 214 (47.9) 90 (20.1) 330 (34.3) 447 (46.5) 184 (19.1) CD 1.18 (0.32–1.69) (CC) 0.38 Jiang 2012
rs2288349 GG GA AA GG GA AA
249  (56.1) 161 (36.3) 34 (7.7) 515 (53.6) 372 (38.7) 74 (7.7) CD 0.81(0.50–1.33) (AA) 0.81 Jiang 2012
rs2114724 CC CT TT CC CT TT
132  (54.5) 97 (40.1) 13 (5.4) 162 (56.2) 101 (35.1) 25 (8.7) CD 1.16 (0.81–1.68) (CT) 0.22 Yang 2012
Dominant 1.23 (0.86–1.76) (CT + TT) 0.27
rs2228611 GG AG AA GG AG AA
132  (54.5) 97 (40.1) 13 (5.4) 160 (56.1) 99 (34.7) 26 (9.1) CD 1.18 (0.81–1.71) (AG) 0.14 Yang 2012
Dominant 1.26 (0.87–1.80) (AG + GG) 0.22
34  (34) 50 (50) 16 (16) 32 (32) 62 (62) 18 (18) CD 1.13 (0.05–6.30) (AG) NA Khatami 2009
rs721186 CC CT TT CC CT TT
99  (99) 1 (1) – 200 (100) – – NA NA NA Khatami 2009
rs13784 CC CT TT CC CT TT
200  (100) – – 100 (100) – – NA NA NA Khatami 2009
rs11488 AA AT TT AA AT TT
200  (100) – – 200 (100) – – NA NA NA Khatami 2009
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Records identified through
database searching
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n Additional records identified
through other sources
(n=0)
Records after duplicates removed
(n=35)
Records screened
(n=35)
Full-text articles
assessed for eligibility
(n=18) 
Full-text articles excluded (n=7)
• MGMT polymorphisms (n=4)
• Only evaluate DNMTs mutations
(n=2)
• Allelic loss in gastric cancer (n=1)
Studies included in
qualitative synthesis
(n=11) 
Records excluded (n =17)
• Do not evaluate DNMTs
polymorphisms (n=9) 
• Do not evaluate polymorphisms
(n=3)
• Not related with gastric cancer
(n=3)
• Review or meta-analysis (n=2)
Fig. 1. Flow chart of studies identiﬁcation, exclusion and inclusion. Adapted from: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting
Items  for Systematic Reviews and Meta-analyses: The PRISMA Statement. PLoS Med  6(6): e1000097. doi:10.1371/journal.pmed1000097.
Table 2.2
Genotyping results for DNMT2 of all studies included.
Gene SNP Genotype distribution n (%) Analysis Model OR (CI) p value Reference
Cases Controls
DNMT2 rs11254413
GG AG AA GG AG AA
204
(84.3)
15
(6.2)
23
(9.5)
187
(63.8)
91
(31.1)
15
(5.1)
CD  0.16 (0.09–0.28) (AG) <0.01 Yang
2012Dominant 0.15 (0.08–0.27) (AG + AA) <0.01
Study or subgroup
5.1.2 rs 16999593 (TT vs TC+CC)
Jiang 2012
Yang 2012
Subtotal (95% CI)
Total events
Tau2=0.00; Chi2=0.33, df=1 (P=.56); l2=0%
Tau2=0.10; Chi2=2.48, df=1 (P=.12); l2=60%
Tau2=0.05; Chi2=2.41, df=1 (P=.12); l2=58%
Heterogeneity:
Test for overall effect: Z=2.73 (P=.006)
5.1.3 rs8101866 (TT vs TC+CC)
Jiang 2012
Yang 2012
Subtotal (95% CI)
Total events
Heterogeneity:
Test for overall effect: Z=.30 (P=.77)
Heterogeneity:
Test for overall effect: Z=.36 (P=.72)
Khatami 2009
Yang 2012
Subtotal (95% CI)
Total events
5.1.6 rs2228611 (GG vs GA+AA)
GC
164
207 447
242
689 1255
294
961 66.1%
33.9%228
435
66 200 80 200 46.4%
53.6%294
494
125242
442
110
176 205
740
268
472
101
265 400
447 302 961
98 294242
689 1255
69.1%
30.9%
100.0%
100.0%
100.0%
1.26 [1.00, 1.60]
1.43 [1.01, 2.04]
1.31 [1.08, 1.60]
0.89 [0.71, 1.12]
1.08 [0.64, 1.84]
0.74 [0.49, 1.11]
0.93 [0.61, 1.40]
0.5 0.7
Low risk High risk
1 1.5 2
0.13 [0.80, 1.59]
1.58 [0.81, 3.10]
Events Events Weight M-H, random, 95% CI
Odds ratio
M-H, random, 95% CI
Odds ratio
TotalTotal
Control
Fig. 2. Forest-plot for DNMT1 SNPs.
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Table 2.3
Genotyping results for DNMT3A of all studies included.
Gene SNP Genotype distribution n (%) Analysis model OR (CI) p value Reference
Cases Controls
DNMT3A
rs7560488
TT TC CC TT TC CC
279
(68.9)
111
(27.4)
15
(3.7)
326
(79.9)
75
(18.4)
7
(1.7)
CD 1.73 (1.24–2.41) (TC); 2.50
(1.01–6.23) (CC)
0.01; 0.04 Wu
2014
Dominant 1.65(1.19–2.29) (TC + CC) 0.002
rs1550117
GG  GA AA GG GA AA
289
(64.7)
142
(31.8)
16
(3.6)
640
(66.6)
288
(30)
33
(3.4)
CD 1.10 (0.83–1.47) (AA) 0.51 Cao
2013Dominant 1.06 (0.83–1.32) (GA  + AA) 0.51
157
(64.9)
74
(30.6)
11
(4.5)
191
(65)
93
(31.6)
10
(3.4)
CD 1.34 (0.55–3.29) (AA) 0.74 Yang
2012Dominant 0.92 (0.63–1.34) (GA  + AA) 0.68
102  (49) 75 (36.1) 31 (14.9) 218(63) 118 (34.1) 10 (2.9) CD 6.63 (3.13–14.03) (AA) 0.00 Fan 2010
rs13420827
CC  CG GG CC CG GG
295
(66)
133
(29.8)
19
(4.3)
618
(64.3)
304
(31.6)
39
(4.1)
CD 1.06 (0.79–1.41) (GG) 0.71 Cao
2013Dominant 1.05(0.83–1.33) (CG + GG) 0.64
167
(69)
61
(25.2)
14
(5.8)
183
(62.7)
99
(33.9)
10
(3.4)
CD 0.68 (0.46–1.01) (CG) 0.05 Yang
2012Dominant 0.66 (0.45–0.97) (CG + GG)  0.03
rs36012910
AA  AG GG AA AG GG
288
(84.71)
51
(15)
1
(0.29)
234
(93.23)
17
(6.77) 0
CD 2.44 (1.37–4.33) (AG) 0.002 Wu
2012Dominant 2.36 (1.35–4.14) (AG + GG)  0.002
rs11887120
TT  TC CC TT TC CC
57  (23.6) 121 (50) 64 (26.4) 74 (25.3) 155 (53.1) 63 (21.6) CD 1.37 (0.88–2.13) (AA) 0.17 Wang 2015
rs13428812
AA  AG GG AA AG GG
137
(56.6)
84
(34.7)
21
(8.7)
160
(55.4)
106
(36.7)
23
(8)
CD 1.11 (0.58–2.12) (GG) 0.84 Yang
2012Dominant 0.91 (0.64–1.31) (AG + GG) 0.63
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158 447 321 961 38.2% 1.09 [0.86, 1.38]
0.93 [0.73, 1.18]
0.76 [0.53, 1.09]
1.80 [1.27, 2.56]
1.00 [0.70, 1.43]
1.24 [0.89, 1.73]
31.1%
30.6%
128 346
103 294
961 70.0%
30.0%294
208
242
447 343
109
452
242
689 1255
897 1601 100.0%
100.0%
107
350
152
75
227
552
85
5.2.2 rs 1550117 (GG vs GA+AA)
Cao 2013
Fan 2010
Cao 2013
Yang 2012
Total events
Subtotal (95% CI)
Yang 2012
Subtotal (95% CI)
5.2.3 rs13420827 (CC vs CG+GG)
Total events
Test for overall effect: Z=1.28 (P=.20)
Heterogeneity: Tau2=0.00; Chi2=0.80, df=1  (P=.37); l2=0%
Test for overall effect: Z=1.32 (P=.19)
0.5 0.7
Low risk High risk
1 1.5 2
Study or subgroup
GC
Events Events Weight M-H, random, 95% CI
Odds ratio
M-H, random, 95% CI
Odds ratio
TotalTotal
Control
Tau2=0.06; Chi2=6.85, df=2 (P=.03); l2=71%Heterogeneity:
0.88 [0.72, 1.07]
Fig. 3. Forest-plot for DNMT3A SNPs (Dominant model).
Study or subgroup
5.3.1 rs1569686 (TT vs TG+GG)
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Risk ratio
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Risk ratio
TotalTotal
Control
Heterogeneity: Tau2=0.34; Chi 2=12.60, df=1  (P=.0004); l 2=92%
Test for overall effect: Z=0.59 (P=.55)
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s16999593 had a statistically signiﬁcant result, revealing a 31%
ncreased risk of GC development for TC + CC genotypes (p = 0.006;
R = 1.31; 95%CI = 1.08–1.60). The rs8101866 and rs2228011
howed no signiﬁcant differences (p > 0.05) and no impact on the
isk (OR = 1.08 and OR = 0.93, respectively) – Fig. 2.
DNMT3A: Statistical analysis showed heterogeneity of studies
or rs1550117 (p = 0.03), and moreover no impact on the risk of
C development for either rs1550117 or rs13420827 (p = 0.20 and
 = 0.19, respectively) – Fig. 3.
DNMT3B: One SNP (rs2424913) was excluded from the meta-
nalysis because there was no data for all genotypes in the three
tudies, making it impossible to estimate the OR value.9,23,24
he analysis also revealed that studies regarding rs1569686 are
ery contradictory, resulting in a high heterogeneity on studies
p < 0.001) and no association with GC – Fig. 4.
iscussion
Gastric carcinogenesis is a multistep process, where different
actors are involved and epigenetic alterations seem to play an
mportant role in early mechanisms of this process.6 DNA CpG
ethylation is catalyzed by DNMTs and modiﬁed DNA methylation
as direct effect on the regulation of gene expression. Consid-
ring the signiﬁcant impact of genetic susceptibility based on
he genetic sequences of individuals, functional SNPs may  affect
NMTs expression, and therefore, it is important to study SNPs in
NMTs and understand the effect that functional SNPs can have on
rotein activity.
Literature reveals that DNMTs are frequently overexpressed in
C.14 Recently, several studies have been performed to evaluate the
mpact of DNMTs polymorphisms in GC susceptibility.3,8–11,19–24
ence, this study intends to resume the data published regarding
he association of SNPs in DNMTs with GC. By searching literature,
e have found 11 studies matching our inclusion criteria. One of0.5 0.7
Low risk High risk
1 1.5 2
 SNPs (Dominant model).
the ﬁrst ﬁndings was  that the majority of included studies were
performed in Asiatic populations, where GC is extremely common,
and therefore this is a major limitation since that is not possible to
extrapolate the conclusions to others populations.25
A total of 24 SNPs were found in this systematic review: 10
in DNMT1, 1 in DNMT2 and 13 in DNMT3. The heterogeneity
found among the included studies is due not only to population
differences but also to different genotyping methods. The geno-
typing methods used had different sensitivity/speciﬁcity: PCR-RFLP
method has some limitations to genotype correctly the three geno-
types, specially heterozygote genotypes26; while TaqMan real-time
PCR assays are more accurate and have less limitations and are a
better candidate for SNP genotyping.27 Furthermore, the number
of cases and controls included are extremely different among stud-
ies and therefore more studies with bigger populations and more
precise genotyping methods are still required.
Our results revealed that DNMT1 rs16999593, DNMT2
rs11254413 and DNMT3A rs7560488 and rs36012910 are the only
SNPs associated with GC.3,8,19 The DNMT1 rs16999593 is charac-
terized by a C>T variation, resulting in an Arg to His amino acid
substitution at position 97 of the protein, leading to missense muta-
tion that may  affect the structure and function of DNMT1. Literature
demonstrated that rs16999593 is signiﬁcantly associated to dif-
ferent malignancies: Tao et al. showed that individuals with TC
genotype had a 4-fold increased risk for sporadic triple-negative
breast carcinoma28; Xiang et al. also revealed that rs16999593
can provide protective effect for ductal breast carcinoma29; and
Yang et al. reported a 1.45-fold increased risk for TC + CC carriers
and GC.3 Although these evidences, other studies do not show any
association.11,30 DNMT2 rs11254413 is characterized by a G>A sub-
stitution leading to an amino acid change, His to Tyr at position 101
of the protein that may  affect DNMT2 function.3 The A-allele was
associated with protection risk for GC by Yang et al., nevertheless,
there is no functional study that support the biological role of this
M. Neves et al. / Porto Biomed
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SNP on DNMT2 function.3 The DNMT3A rs7560488 (variation T>C)
is a tagSNP that represents SNPs of the DNMT3A1 promoter with
high linkage disequilibrium and has been associated with higher
risk for GC in Asiatic population.8 Authors suggested that T to C
change inﬂuences the binding of transcriptional factors and conse-
quently expression levels of DNMT3A.8 The DNMT3A rs36012910,
which is characterized by a A>G substitution, is located in the pro-
moter region of DNMT3A and the substitution has been associated
with DNMT3A altered activity.19 Wu  et al. reveals that AG + GG
genotypes were associated with a higher risk for GC.19
Regarding the data from the meta-analysis, we only were able to
compare the results of 6 SNPs, which were described in more than
one study. For DNMT1 analysis, 3 SNPs were studied (rs16999593,
rs8101866 and rs2228611) and only rs16999593 showed statisti-
cally signiﬁcance3,22 – Fig. 2. The results showed an increased risk
for TC + CC genotypes of GC development. Nevertheless, the low
number of studies and the lack of studies from populations apart
from China make it necessary to perform more studies with differ-
ent populations to conﬁrm the association of rs16999593 with GC.
Concerning DNMT3A, 2 SNPs were included in the meta-analysis
(rs1550117 and rs13420827) but no association with GC was found
– Fig. 3. The analysis revealed heterogeneity in rs1550117 dis-
tribution in populations, especially when comparing the report
by Fan et al. to the other studies (Fan et al., 2010). Nevertheless,
even removing Fan et al. from the analysis there was no signiﬁcant
association of rs1550117 with GC development. Furthermore, the
differences in genotype distribution might be explained because of
different genotype methods used in the three studies – Table 1.
Finally, we included one SNP in DNMT3B on the meta-analysis
(rs1569686) that showed no association with GC – Fig. 4. The anal-
ysis revealed heterogeneity in the distribution and a signiﬁcant
difference in the OR of the two studies (OR = 0.43 in Hu et al. and
OR = 1.21 in Wang et al.).9,10
Conclusions
We have found 11 articles studying SNPs in DNMTs but the vari-
ety of SNPs and the reduced number of studies per each SNP made
this analysis complicated, allowing us to draw only some remarks
and not strong conclusions. The data from studies revealed that
rs11254413, rs7560488, rs36012910 and, specially, rs16999593
seem to be good candidates to be studied for their role in GC devel-
opment. Nevertheless, our meta-analysis revealed that only one
SNP (rs16999593) in DNMT1 was  associated with GC development,
especially TC + CC carriers.
More studies with different populations are required to prove
if the SNPs selected in our analysis are associated with GC  and
furthermore, studies regarding biological importance of functional
SNPs in DNMTs activity and expression are also needed to fully
understand the impact of these SNPs in DNMTs on GC.
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